Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity

Arthritis and Rheumatology

Volumn 68, Issue 10, 2016, Pages 2492-2502

  Slight Webb, Samantha ^a   Lu, Rufei ^b   Ritterhouse, Lauren L ^b   Munroe, Melissa E ^a   Maecker, Holden T ^c   Fathman, Charles G ^c   Utz, Paul J ^c   Merrill, Joan T ^a   Guthridge, Joel M ^b   James, Judith A ^b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P40; INTERLEUKIN 17; STAT1 PROTEIN; STAT3 PROTEIN; STEM CELL FACTOR; TUMOR NECROSIS FACTOR; ANTINUCLEAR ANTIBODY; CENPB PROTEIN, HUMAN; CENTROMERE ANTIBODY; CENTROMERE PROTEIN B; IL1RN PROTEIN, HUMAN; JO-1 ANTIBODY; NUCLEAR PROTEIN; PHOSPHOPROTEIN; RIBONUCLEOPROTEIN; RIBOSOME PROTEIN; SCL 70 ANTIGEN, HUMAN; SS-A ANTIBODIES; SS-B ANTIBODIES; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MALE; MEMORY CELL; PLASMABLAST; PRIORITY JOURNAL; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; B LYMPHOCYTE SUBPOPULATION; CASE CONTROL STUDY; DRUG EFFECTS; IMMUNOLOGY; LEUKOCYTE; MIDDLE AGED; MONOCYTE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; PLASMA CELL; SEX DIFFERENCE; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTE SUBSETS; CASE-CONTROL STUDIES; CENTROMERE PROTEIN B; CYTOKINES; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEALTHY VOLUNTEERS; HUMANS; IMMUNOPHENOTYPING; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-17; LEUKOCYTES; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PLASMA CELLS; RIBONUCLEOPROTEINS; RIBOSOMAL PROTEINS; SEX FACTORS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STEM CELL FACTOR; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84988864250     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39706     Document Type: Article

References (50)

1. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64:2319–27.
2. Parks CG, Miller FW, Satoh M, Chan EK, Andrushchenko Z, Birnbaum LS, et al. Reproductive and hormonal risk factors for antinuclear antibodies (ANA) in a representative sample of U.S. women. Cancer Epidemiol Biomarkers Prev 2014;23:2492–502.
3. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007;56:2344–51.
4. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526–33.
5. Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011;13:R38.
6. Olsen NJ, Li QZ, Quan J, Wang L, Mutwally A, Karp DR. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther 2012;14:R174.
7. Calvo-Alen J, Alarcon GS, Burgard SL, Burst N, Bartolucci AA, Williams HJ. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol 1996;23:469–75.
8. Hallengren CS, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus 2004;13:85–8.
9. Grieco FA, Vendrame F, Spagnuolo I, Dotta F. Innate immunity and the pathogenesis of type 1 diabetes. Semin Immunopathol 2011;33:57–66.
10. Schwartz M, Kipnis J. Autoimmunity on alert: naturally occurring regulatory CD4+CD25+ T cells as part of the evolutionary compromise between a ‘need’ and a ‘risk’. Trends Immunol 2002;23:530–4.
11. Lang KS, Burow A, Kurrer M, Lang PA, Recher M. The role of the innate immune response in autoimmune disease. J Autoimmun 2007;29:206–12.
12. Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008;17:394–9.
13. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610–5.
14. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307–36.
15. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973–7.
16. Becker AM, Dao KH, Han BK, Kornu R, Lakhanpal S, Mobley AB, et al. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PloS One 2013;8:e67003.
17. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711–23.
18. Hirai M, Kadowaki N, Kitawaki T, Fujita H, Takaori-Kondo A, Fukui R, et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 2011;117:500–9.
19. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005;202:1575–85.
20. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417–28.
21. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-α (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Med 1999;115:196–202.
22. Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010;207:2931–42.
23. Yasuda K, Richez C, Uccellini MB, Richards RJ, Bonegio RG, Akira S, et al. Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J Immunol 2009;183:3109–17.
24. Harada T, Kyttaris V, Li Y, Juang YT, Wang Y, Tsokos GC. Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity 2007;40:1–8.
25. Huang X, Guo Y, Bao C, Shen N. Multidimensional single cell based STAT phosphorylation profiling identifies a novel biosignature for evaluation of systemic lupus erythematosus activity. PLoS One 2011;6:e21671.
26. Hale MB, Krutzik PO, Samra SS, Crane JM, Nolan GP. Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus. PLoS One 2009;4:e6756.
27. Karlson EW, Sanchez-Guerrero J, Wright EA, Lew RA, Daltroy LH, Katz JN, et al. A connective tissue disease screening questionnaire for population studies. Ann Epidemiol 1995;5:297–302.
28. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
29. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al, for the OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.
30. Maier-Moore JS, Koelsch KA, Smith K, Lessard CJ, Radfar L, Lewis D, et al. Antibody-secreting cell specificity in labial salivary glands reflects the clinical presentation and serology in patients with Sjogren's syndrome. Arthritis Rheumatol 2014;66:3445–56.
31. Stringer EA, Baker KS, Carroll IR, Montoya JG, Chu L, Maecker HT, et al. Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology. J Trans Med 2013;11:93.
32. Genuer R, Poggi JM, Tuleau-Malot C. Variable selection using random forests. Pattern Recogn Lett 2010;31:2225–36.
33. Lee HM, Sugino H, Nishimoto N. Cytokine networks in systemic lupus erythematosus. J Biomed Biotech 2010;2010:676284.
34. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010;10:89–102.
35. Dorner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods 2011;363:187–97.
36. Konya C, Paz Z, Tsokos GC. The role of T cells in systemic lupus erythematosus: an update. Curr Opin Rheumatol 2014;26:493–501.
37. Saverino D, Fabbi M, Merlo A, Ravera G, Grossi CE, Ciccone E. Surface density expression of the leukocyte-associated Ig-like receptor-1 is directly related to inhibition of human T-cell functions. Hum Immunol 2002;63:534–46.
38. Dietrich J, Cella M, Colonna M. Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol 2001;166:2514–21.
39. Monsivais-Urenda A, Gomez-Martin D, Santana-de-Anda K, Cruz-Martinez J, Alcocer-Varela J, Gonzalez-Amaro R. Defective expression and function of the ILT2/CD85j regulatory receptor in dendritic cells from patients with systemic lupus erythematosus. Hum Immunol 2013;74:1088–96.
40. Monsivais-Urenda A, Nino-Moreno P, Abud-Mendoza C, Baranda L, Layseca-Espinosa E, Lopez-Botet M, et al. Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J Autoimmun 2007;29:97–105.
41. Wlasiuk P, Tomczak W, Zajac M, Dmoszynska A, Giannopoulos K. Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients. Hum Immunol 2013;74:1592–7.
42. Kyu SY, Kobie J, Yang H, Zand MS, Topham DJ, Quataert SA, et al. Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells. J Immunol Methods 2009;340:42–7.
43. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000;18:565–70.
44. Song GG, Kim JH, Seo YH, Choi SJ, Ji JD, Lee YH. Associations between interleukin 1 polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis. Hum Immunol 2014;75:105–12.
45. Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 1997;36:1283–9.
46. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25:401–6.
47. Lopez P, Scheel-Toellner D, Rodriguez-Carrio J, Caminal-Montero L, Gordon C, Suarez A. Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes. Rheumatology (Oxford) 2014;53:2249–58.
48. Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. Trends Immunol 2007;28:33–8.
49. Slight SR, Lin Y, Messmer M, Khader SA. Francisella tularensis LVS-induced Interleukin-12 p40 cytokine production mediates dendritic cell migration through IL-12 receptor β1. Cytokine 2011;55:372–9.
50. Robinson RT, Khader SA, Locksley RM, Lien E, Smiley ST, Cooper AM. Yersinia pestis evades TLR4-dependent induction of IL-12(p40)2 by dendritic cells and subsequent cell migration. J Immunol 2008;181:5560–7.